TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04494399
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day course of oral ribavirin 400mg twice daily
Study: NCT03308591
Drug: NACT
Normalized name: Nacton
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Platin based chemotherapy
Study: NCT01677884
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
Study: NCT00426933
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00426933
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01677884
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
Study: NCT04623879
Drug: Lumacaftor, Ivacaftor Drug Combination
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04447352
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study: NCT04447352
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study: NCT00162318
Drug: Cetuximab + Gefitinib
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
Study: NCT04447352
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 q2w: 50 mg/m² IV over 1 hour
Study: NCT04447352
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
Study: NCT02150733
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
Study: NCT02150733
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
Study: NCT02150733
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
Study: NCT02150733
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
Study: NCT00006251
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00006251
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00006251
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02284607
Drug: MHAA4549A
Normalized name: MHAA4549A
DrugBank: Gedivumab (DB15277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A single, intravenous dose administration, lower dose level
Study: NCT02284607
Drug: MHAA4549A
Normalized name: MHAA4549A
DrugBank: Gedivumab (DB15277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A single, intravenous dose administration, higher dose level
Study: NCT02251145
Drug: Tipranavir low dose
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02251145
Drug: Ritonavir low dose
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02054429
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
Study: NCT01314066
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
Study: NCT02251145
Drug: Ritonavir high dose
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02251145
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00860457
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
Study: NCT00860457
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
Study: NCT00860457
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
Study: NCT02068053
Drug: [14C] BMS-986020
DrugBank: BMS-986020 (DB14948)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01696500
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03409432
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03409432
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02383043
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02383043
Drug: Sustained Release d-Amphetamine
Normalized name: amphetamine / dextroamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03544099
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg Intravenous Solution
Study: NCT03486678
Drug: SHR-1210+GEMOX
Normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
Study: NCT03144271
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
Study: NCT05488990
Drug: AKVANO-Calcipotriol formulation 1
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
Study: NCT01009879
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg SQ qweek
Study: NCT05271058
Drug: Dexamethasone group
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
Study: NCT05271058
Drug: Triamcinolone (TA) group
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
Study: NCT00253344
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
Study: NCT00253344
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
Study: NCT04274270
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
Study: NCT01253525
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
Study: NCT00889057
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg bid until progression or inacceptable toxicity
Study: NCT00876915
Drug: dalteparin injection
Normalized name: dalteparin Injection
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
Study: NCT01007864
Drug: piribedil
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
Study: NCT01007864
Drug: pramipexole or ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuation of pre-study treatment regimen
Study: NCT03644485
Drug: Tacrolimus immediate-release formulation
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT03644485
Drug: Tacrolimus prolonged-release formulation
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT05488990
Drug: AKVANO-Calcipotriol formulation 2
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
Study: NCT03917940
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride 2 mg or 3 mg per day oral
Study: NCT00048230
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01321554
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Study: NCT01760967
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intervention to administer dexmedetomidine or not
Study: NCT01321554
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.
Study: NCT05488990
Drug: Daivonex solution
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivonex solution containing Calcipotriol (50 μg/g)
Study: NCT05488990
Drug: Daivonex cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivonex cream containing Calcipotriol (50 μg/g)
Study: NCT00048932
Drug: Double-blind Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
Study: NCT00048932
Drug: Open-label Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
Study: NCT03054766
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: all subjections received 3+PRN ranibizumab injections by BCVA stabilization
Study: NCT00731562
Drug: Varenicline Tartrate Controlled Release
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
Study: NCT01444690
Drug: Dimiracetam
Normalized name: Dimiracetam
DrugBank: Dimiracetam (DB13018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration twice daily
Study: NCT01444690
Drug: Dimiracetam 25 mg
Normalized name: Dimiracetam
DrugBank: Dimiracetam (DB13018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive dose level in capsules administered orally twice daily
Study: NCT00729794
Drug: Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR
Study: NCT01986881
Drug: Ertugliflozin
Normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral, once daily, for up to approximately 6 years
Study: NCT01986881
Drug: Glycemic Rescue
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
Study: NCT01323595
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill PO BID x 6 days
Study: NCT02856724
Drug: PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg PGE2 vaginal ovul(Propess)
Study: NCT02729038
Drug: Gepotidacin
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
Study: NCT02222480
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222480
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00650169
Drug: Clopidogrel Bisulfate Tablets 75 mg
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg, single dose fed
Study: NCT03134846
Drug: Cetuximab-IRDye800CW
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
Study: NCT04229602
Drug: Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
Study: NCT01308606
Drug: TMC435 HPMC or gelatin capsule
Normalized name: Gelatine
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of one 150-mg capsule after high-fat breakfast
Study: NCT01308606
Drug: TMC435 HPMC or gelatin capsule
Normalized name: Gelatine
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of one 150-mg capsule without food
Study: NCT01308606
Drug: TMC435 HPMC or gelatin capsule
Normalized name: Gelatine
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of one 150-mg capsule after standardized breakfast
Study: NCT01308606
Drug: TMC435 gelatin capsule
Normalized name: Gelatine
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of one 150-mg capsule without food
Study: NCT02350712
Drug: Patritumab
Normalized name: Patritumab
DrugBank: Patritumab (DB12090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
Study: NCT02350712
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
Study: NCT02350712
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
Study: NCT02350712
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
Study: NCT02238925
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00695786
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00847405
Drug: Sumatriptan Succinate
Normalized name: Sumatriptan Succinate
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Tablets
Study: NCT02607982
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
Study: NCT02607982
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
Study: NCT00777049
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hard gelatine capsule - 5mg and 20mg
Study: NCT00002801
Drug: tegafur-uracil
Normalized name: Tegafur-uracil
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02236611
Drug: Umeclidinium
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
Study: NCT02236611
Drug: Glycopyrronium
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
Study: NCT00163501
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02309437
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use oxycodone to treat patients with mild pain caused by radiation mucositis.
Study: NCT02309437
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.